Ameliorative effect and mechanism of Sanwei ganlu on hepatic fibrosis in rats

CHEN Xiumei; WANG Yingjie; ZHAO Chengzhou; LI Zhen; ZHANG Wenhuiping; LUO Tangjun; LIU Xin; SUN Shengnan

doi:10.6039/j.issn.1001-0408.2024.06.12

您当前的位置：

首页 >

文章列表页 >

Ameliorative effect and mechanism of Sanwei ganlu on hepatic fibrosis in rats

更新时间：2024-04-09

- Ameliorative effect and mechanism of Sanwei ganlu on hepatic fibrosis in rats
- ZHONGGUO YAOFANG Vol. 35, Issue 6, Pages: 707-711(2024)
- 作者机构：
  
  1.青海大学医学部药学系，西宁　810016
  2.青海大学藏医学院，西宁　810016
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.06.12
  CLC： R965;R285.5
- Published：30 March 2024，
  
  Received：21 November 2023，
  
  Revised：04 March 2024，
扫描看全文
陈秀梅,王英杰,赵成周等.三味甘露对大鼠肝纤维化的改善作用及机制 ^Δ[J].中国药房,2024,35(06):707-711.

CHEN Xiumei,WANG Yingjie,ZHAO Chengzhou,et al.Ameliorative effect and mechanism of Sanwei ganlu on hepatic fibrosis in rats[J].ZHONGGUO YAOFANG,2024,35(06):707-711.
陈秀梅,王英杰,赵成周等.三味甘露对大鼠肝纤维化的改善作用及机制 ^Δ[J].中国药房,2024,35(06):707-711. DOI： 10.6039/j.issn.1001-0408.2024.06.12.

CHEN Xiumei,WANG Yingjie,ZHAO Chengzhou,et al.Ameliorative effect and mechanism of Sanwei ganlu on hepatic fibrosis in rats[J].ZHONGGUO YAOFANG,2024,35(06):707-711. DOI： 10.6039/j.issn.1001-0408.2024.06.12.

摘要

目的

探讨藏药三味甘露对大鼠肝纤维化的改善作用及机制。

方法

实验大鼠分为正常组、模型组、水飞蓟宾组（阳性对照，50 mg/kg）和三味甘露低、中、高剂量组（80、250、800 mg/kg），除正常组外，其余组以四氯化碳（CCl

）腹腔注射诱导大鼠肝纤维化模型。造模给药第6周开始，各组大鼠分别灌胃生理盐水或相应药物。第9周实验结束，计算大鼠肝脏指数和脾脏指数；以苏木素-伊红、Masson及Sirus Red染色观察肝组织病理结构和纤维化程度；检测血清中丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、Ⅲ型前胶原（PC Ⅲ）、Ⅳ型胶原（COL-Ⅳ）、白细胞介素6（IL-6）、肿瘤坏死因子α（TNF-α）、IL-1β含量与肝组织中透明质酸（HA）、层粘连蛋白（LN）含量。

结果

与模型组相比，三味甘露各剂量组和水飞蓟宾组大鼠肝损伤和胶原纤维沉积均有不同程度改善，血清中ALT、AST、PC Ⅲ、COL-Ⅳ、IL-6、TNF-α、IL-1β含量以及肝组织中HA、LN含量均显著降低（

＜0.05或

＜0.01）。

结论

三味甘露能够通过抑制胶原纤维生成，降低转氨酶、HA、LN、PC Ⅲ和COL-Ⅳ含量，减轻炎症反应，从而缓解CCl

诱导的大鼠肝纤维化进程。

Abstract

OBJECTIVE

To investigate the ameliorative effects and mechanism of Sanwei ganlu on hepatic fibrosis in rats.

METHODS

The rats were randomly divided into normal group， model group， silibinin group （positive control， 50 mg/kg）， and Sanwei ganlu low-dose， medium-dose， and high-dose groups （80， 250， 800 mg/kg）. Except for normal group， hepatic fibrosis rat models were established by intraperitoneal injection of CCl

in the other groups of rats. Starting from the 6th week of modeling administration， they were given normal saline or corresponding drugs intragastrically at the same time. At the end of the ninth-week experiment， liver and spleen indexes of rats were calculated； the pathological structure and fibrosis changes of liver tissue were observed by HE， Masson and Sirus Red staining. The contents of alanine transaminase （ALT）， aspartate transaminase （AST）， procollagen type Ⅲ （PC Ⅲ）， collagen type Ⅳ （COL-Ⅳ）， interleukin-6 （IL-6）， tumor necrosis factor-α （TNF-α） and IL-1β in serum， and hyaluronic acid （HA） and laminin （LN） in liver tissue were all detected.

RESULTS

Compared with the model group， the liver injury and collagen fiber deposition of rats were improved to different extents in Sanwei ganlu groups and silibinin group； the contents of ALT， AST， PC Ⅲ， COL-Ⅳ， IL-6， TNF-α and IL-1β in serum as well as the contents of HA and LN in liver tissue significantly decreased （

＜0.05 or

＜0.01）.

CONCLUSIONS

Sanwei ganlu can alleviate the progression of hepatic fibrosis in rats， possibly by inhibiting the synthesis of collagen fiber， reducing transaminase content， down-regulating the levels of HA， LN， PC Ⅲ and COL-Ⅳ， and reducing the inflammatory response.

关键词

三味甘露肝纤维化炎症病理改变胶原蛋白

Keywords

hepatic fibrosisinflammationpathological changescollagen

references

DEVARBHAVI H，ASRANI S K，ARAB J P，et al. Global burden of liver disease：2023 update[J]. J Hepatol，2023，79（2）：516-537.

TANWAR S，RHODES F，SRIVASTAVA A，et al. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C[J]. World J Gastroenterol，2020，26（2）：109-133.

ZHENG X Q，WU Z，XU J，et al. Bioactive sesquiterpenes from Inula helenium[J]. Bioorg Chem，2021，114：105066.

仁青罗布. 浅谈藏药寒水石的传统炮制方法[J]. 西藏科技，2017（10）：8-9.

Renqingluobu. Discussion on the traditional processing method of Tibetan medicine mirabilite[J]. Tibet Sci Technol，2017（10）：8-9.

LV Y，LI C Z，WANG Z，et al. Preparative isolation of antioxidative furanocoumarins from Dracocephalum heterophyllum and their potential action target[J]. J Sep Sci，2022，45（24）：4375-4387.

索科. 三味甘露灵活组方原创性配伍思维及临床疗效研究[D]. 北京：北京中医药大学，2020.

SUO K. Study on original compatibility thinking and clinical efficacy of Sanwei Ganlu flexible formula[D].Beijing：Beijing University of Chinese Medicine，2020.

OJEABURU S I，ORIAKHI K. Hepatoprotective，antioxidant and，anti-inflammatory potentials of gallic acid in carbon tetrachloride-induced hepatic damage in Wistar rats[J]. Toxicol Rep，2021，8：177-185.

龚普阳，尹可欢，李雪冬，等. 藏药防治肝纤维化的临床与药理研究进展[J]. 药学学报，2021，56（11）：2995-3003.

GONG P Y，YIN K H，LI X D，et al. Clinical and pharmacological research progress of Tibetan medicine in prevention and treatment for hepatic fibrosis[J]. Acta Pharm Sin，2021，56（11）：2995-3003.

嘎玛格勒，米玛，陈静，等. 藏药三味甘露散的方剂来源、炮制工艺及配伍特点综述[J]. 亚太传统医药，2022，18（12）：10-13.

Gamagele，MI M，CHEN J，et al. The source，processing technology and compatibility characteristics of Tibetan medicine Sanwei Ganlu Powder[J]. Asia Pac Tradit Med，2022，18（12）：10-13.

艾丁丁，罗伟生，蒋云霞. 动物肝纤维化模型建立研究进展[J]. 陕西医学杂志，2020，49（7）：907-909.

AI D D，LUO W S，JIANG Y X. Progress in the establishment of animal liver fibrosis model[J]. Shaanxi Med J，2020，49（7）：907-909.

沈悦，屈祥科，聂桐荷，等. 基于“治肝实脾” 理论论治酒精性肝纤维化[J]. 中医药学报，2023，51（7）：11-14.

SHEN Y，QU X K，NIE T H，et al. Treatment of alcoholic liver fibrosis based on the theory of “treating liver and strengthening spleen” [J]. Acta Chin Med Pharmacol，2023，51（7）：11-14.

吴晓东，张峰，梁瑞峰. 大黄素与丹参素合用对四氯化碳诱导大鼠肝纤维化的保护作用[J]. 天津中医药，2018，35（2）：143-146.

WU X D，ZHANG F，LIANG R F. Effects of combination of emodin and tanshinol in hepatic fibrosis rats induced by carbon tetrachloride[J]. Tianjin J Tradit Chin Med，2018，35（2）：143-146.

胡明政，秦春宏. 肝纤维化发病机制的研究进展[J]. 西南军医，2017，19（2）：155-157.

HU M Z，QIN C H. Research progress on pathogenesis of liver fibrosis[J]. J Mil Surg Southwest China，2017，19（2）：155-157.

张梦师，黄奕璇，李洁莲，等. 棒柄花叶提取物对肝纤维化大鼠的防治作用及其机制[J]. 广西医科大学学报，2022，39（8）：1217-1223.

ZHANG M S，HUANG Y X，LI J L，et al. Preventive effect of water extract of Cleidion brevipetiolatum leaves on hepatic fibrosis in rats and its mechanism[J]. J Guangxi Med Univ，2022，39（8）：1217-1223.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

红丝线多糖对鼠源肝星状HSCs-T6 细胞增殖的抑制作用及其机

Protective Effect and Mechanism of Tadehaginoside on Hepatic Fibrosis Model Mice Induced by Carbon Tetra- chloride

Related Author

HE Silu

GUO Xiaobao

XU Lingyuan

JIAO Aijun

TANG Aicun

WEI Yanfei

LIU Xihua

WANG Minggang

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰